Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533597 | 1.00 | HTT (0.31) | HTTSMN1; SMN2ALDH1A1BAP1 | |
| SCHEMBL31208849 | 0.94 | SMN1; SMN2 (0.31) | HTTSMN1; SMN2 | |
| SCHEMBL31209719 | 0.94 | HTT (0.32) | HTTSMN1; SMN2ALDH1A1BAP1 | |
| SCHEMBL31209068 | 0.93 | THRB (0.32) | HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL26118425 | 0.90 | ALDH1A1 (0.32) | HTTSMN1; SMN2ALDH1A1BAP1 | |
| SCHEMBL31209328 | 0.88 | HTT (0.31) | HTTSMN1; SMN2ALDH1A1BAP1 | |
| SCHEMBL30776559 | 0.88 | — | — | |
| SCHEMBL26535717 | 0.88 | — | — | |
| SCHEMBL26533564 | 0.88 | — | — | |
| SCHEMBL31123181 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250101043-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-03-27 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTT 2914/4885SMN1; SMN2 4212/4885ALDH1A1 1852/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | HTT 2914/4885SMN1; SMN2 4212/4885ALDH1A1 1852/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTT 2813/4885SMN1; SMN2 4044/4885ALDH1A1 2134/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTT 2914/4885SMN1; SMN2 4212/4885ALDH1A1 1852/4885 |
| US-20250101043-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTT 2813/4885SMN1; SMN2 4044/4885ALDH1A1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.